证券代码：600530 证券简称：*ST 交昂 公告编号：临 2023-077 ● 根据《股票上市规则》第9.4.13条第（二）项规定，若公司股票被实施退市风 险警示后2个月内仍未披露经审计的2022年年度报告和2023年第一季度报告，公司股票 将被终止上市。敬请广大投资者注意投资风险。 一、股票交易异常波动的具体情况 公司股票在8月7日、8月8日、8月9日连续三个交易日内收盘价格涨幅偏离值累计 超12%，根据《上海证券交易所交易规则（2023年修订）》的相关规定，属于股票交易 异常波动情形。 二、公司关注并核实的相关情况 上海交大昂立股份有限公司 关于公司股票交易异常波动的公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 上海交大昂立股份有限公司（以下简称"公司"）股票在8月7日、8月8日、8 月9日连续三个交易日内收盘价格涨幅偏离值累计超12%，根据《上海证券交易所交易 规则（2023年修订）》的相关规定，属于股票交易异常波动情形。 ● 经公司自查及书面发函询问控股股东、实际控制人，截止本公告披露日 ...

关于增补第八届监事会监事候选人的公告 本公司监事会及全体监事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600530 证券简称：*ST 交昂 公告编号：临 2023-075 上海交大昂立股份有限公司 上海交大昂立股份有限公司（以下简称"公司"）股东监事李一贺先生、朱莹政 先生已辞任第八届监事会股东监事。具体内容详见公司于 2023 年 1 月 21 日、4 月 28 日披露的《关于公司监事辞职及补选职工代表监事的公告》《关于公司监事辞职的公 告》（公告编号：临 2023-005、临 2023-021）。 经公司股东上海韵简实业发展有限公司及其一致行动人上海饰杰装饰设计工程有 限公司推荐，在征得本人同意后，公司第八届监事会第十一次会议审议通过了《关于增 补第八届监事会监事候选人的议案》（同意 3 票，反对 0 票，弃权 0 票），公司监事会同 意提名张顺先生、李家儒先生为公司第八届监事会监事候选人（简历见附件），任期自 公司股东大会审议通过之日起至本届监事会任期届满之日止，并将此议案作为临时提案 提交公司 2023 年第四次临时股东大会 ...

2022 年第三季度报告 证券代码：600530 证券简称：交大昂立 上海交大昂立股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 | 稀释每股收益（元/股） | 0.03 | 708.55 | 0.05 | | | 57.94 | | --- | --- | --- | --- | --- | --- | --- | | 加权平均净资产收益率 | 2.8 | 增加 2.40 | 4.13 | 增加 | 1.32 个百 | | | （%） | | 个百分点 | | | 分点 | | | | 本报告期末 | | 上年度末 | 本报告期末比 上年度末增减 | | | | | | | | 变动幅度(%) | | | | 总资产 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥161,912,619.04, a decrease of 9.24% compared to ¥178,398,351.17 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was ¥11,731,826.35, down 42.56% from ¥20,424,555.96 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,990,071.24, a decrease of 26.40% compared to ¥16,289,819.66 in the same period last year[21]. - Basic earnings per share decreased by 42.15% to CNY 0.015 compared to the previous period[23]. - Diluted earnings per share also decreased by 42.15% to CNY 0.015[23]. - The weighted average return on equity dropped by 0.98 percentage points to 1.33%[23]. - The company reported a total of CNY -258,244.89 in non-recurring losses after tax adjustments[25]. - The net profit for the first half of 2022 was CNY 13,439,891.33, a decline of 41.9% compared to CNY 23,128,202.61 in the first half of 2021[104]. - The company reported a total comprehensive income of CNY 8,882,355.32, down from CNY 24,344,292.52 year-on-year[105]. Cash Flow and Assets - The net cash flow from operating activities increased by 6.18% to ¥41,495,647.66 from ¥39,080,452.35 in the previous year[21]. - The total assets at the end of the reporting period were ¥1,403,191,152.75, an increase of 3.76% from ¥1,352,345,202.99 at the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were ¥883,024,939.34, up 0.82% from ¥875,850,649.00 at the end of the previous year[21]. - The total cash and cash equivalents at the end of the period were 167,094,608.20 RMB, up from 86,402,028.05 RMB at the end of the first half of 2021[111]. - The total liabilities increased to CNY 480,739,699.81, compared to CNY 438,776,105.37 at the beginning of the period, reflecting an increase of 9.6%[96]. - The company's equity attributable to shareholders rose to CNY 883,024,939.34, up from CNY 875,850,649.00, marking an increase of 0.1%[96]. Business Operations - The main business includes the R&D, production, and sales of food and health food products, as well as the operation and management of elderly medical care institutions[26]. - The health food segment's production includes self-produced and outsourced products, with various product lines such as oral liquids and capsules[27]. - The sales model combines offline and online channels, with offline sales through major retailers and pharmacies, and online sales through TV shopping and e-commerce[28]. - The health food industry is expected to grow due to increasing disposable income and a rising willingness to pay for health products[28]. - The company anticipates that the demand for functional health foods will create greater market opportunities in the future[28]. - The company's medical care segment generated a total operating income of RMB 81.1 million, with a net profit attributable to the parent company of RMB 22.9 million during the reporting period[39]. - The total number of beds occupied at the end of June was 2,805, reflecting a year-on-year decrease of approximately 3.5% due to pandemic-related restrictions[39]. Risk Management - The company has detailed potential risks in the management discussion and analysis section of the report[7]. - The company faces risks from strict industry regulations, raw material price fluctuations, and reliance on medical insurance payments[50]. Corporate Governance - The company held two shareholder meetings during the reporting period, complying with legal regulations and ensuring valid resolutions[55]. - The board of directors underwent significant changes, with new appointments including Ji Lin as Chairman and Zhang Yunjian as President[56]. - The company has not reported any significant changes in its corporate governance structure beyond the recent board elections[57]. Environmental Responsibility - The company faced an administrative fine of 360,000 RMB due to environmental compliance issues related to wastewater treatment[61]. - The company is committed to environmental responsibility, conducting regular maintenance on wastewater systems to prevent leaks[62]. - The company implemented energy-saving measures in its boilers, achieving an annual reduction of approximately 195 tons of standard coal through improved heat recovery[63]. Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders is 34,819[79]. - The largest shareholder, Dazhong Transportation Group Co., Ltd., holds 14.38% of the shares, totaling 112,184,187 shares[81]. - Shanghai Yunjian Industrial Development Co., Ltd. holds 10.56% of the shares, totaling 82,362,600 shares[82]. - The company approved a share repurchase plan with a total amount not less than RMB 25 million and not exceeding RMB 50 million, with a maximum repurchase price of RMB 6.91 per share[84]. Research and Development - R&D expenses increased due to higher investment in research and development[42]. - The company has obtained 34 national patent authorizations, including 9 for probiotic inventions, showcasing its strong technological capabilities[31]. Financial Management - The company has established a cost control analysis system to monitor operational costs across various levels, enhancing its competitive advantage in cost management[36]. - The company has achieved a significant reduction in financial expenses by 75.97%, from RMB 8.9 million to RMB 2.1 million[40]. - The company reported a decrease in investment income due to the disposal of Suzhou Sanxiang Road Elderly Apartment in the previous period[42]. Compliance and Reporting - The report has not been audited, and the management has confirmed the accuracy and completeness of the financial report[5]. - The financial statements are prepared based on the enterprise accounting standards, reflecting the company's financial status and operating results accurately[136].

Financial Performance - In 2021, the company's operating revenue was CNY 362,576,663.60, an increase of 8.98% compared to CNY 332,695,487.68 in 2020[21] - The net profit attributable to shareholders of the listed company for 2021 was CNY 37,177,627.01, a decrease of 59.88% from CNY 92,670,121.92 in 2020[21] - The net profit after deducting non-recurring gains and losses was CNY 25,330,968.24, representing a significant increase of 258.85% compared to CNY 7,058,882.62 in 2020[21] - The cash flow from operating activities for 2021 was CNY 104,062,540.92, up 54.90% from CNY 67,178,715.33 in 2020[21] - The total revenue for the year 2021 was 363 million RMB, representing a year-on-year increase of 8.98%[45] - The net profit attributable to shareholders was 37 million RMB, a significant decrease of 59.88% compared to the previous year, primarily due to the sale of a subsidiary[45] Assets and Liabilities - As of the end of 2021, the total assets amounted to CNY 1,352,345,202.99, an increase of 4.51% from CNY 1,293,961,078.31 at the end of 2020[21] - The net assets attributable to shareholders of the listed company were CNY 875,850,649.00, reflecting a 4.90% increase from CNY 834,900,061.69 in 2020[21] - Cash and cash equivalents increased by 38.49% to 163.43 million yuan, accounting for 12.08% of total assets[61] - Inventory rose by 29.57% to 55.67 million yuan, representing 4.12% of total assets[61] - Long-term equity investments decreased by 59.23% to 27.71 million yuan, accounting for 2.05% of total assets[61] - Short-term borrowings decreased by 37.50% to 50 million yuan, representing 3.70% of total liabilities[61] Profitability and Margins - Basic earnings per share for 2021 were CNY 0.05, down 57.98% from CNY 0.119 in 2020[22] - The weighted average return on equity decreased by 7.04 percentage points to 4.17% in 2021[23] - The company achieved a gross profit margin of 43.0% in its main business operations, indicating stable profitability[50] - The gross profit margin for the overall business was 42.83%, reflecting an increase of 2.29 percentage points from the previous year[51] - The gross profit margin for the health products segment was 58.67%, which increased by 13.23 percentage points[54] Business Segments and Growth - The company achieved a turnaround in the health product segment, marking its first profit in nearly seven years[29] - The raw material business saw significant growth, particularly in exports, due to enhanced R&D efforts and improved production management[29] - The healthcare segment reported a revenue of CNY 159,768,650.32, with a year-on-year growth of 37.49%[51] - The company operates six self-managed profit-oriented elderly medical care institutions, providing services such as medical care, rehabilitation, nursing, and health management[40] - The company’s health supplement products include probiotics and herbal extracts, targeting various health needs such as immune enhancement and blood lipid regulation[36] Research and Development - The company's R&D expenses increased by 22.65% to 15.64 million RMB, reflecting a commitment to technological innovation[47] - The company holds 18 Chinese invention patents, including 11 related to probiotics, showcasing its strong technological capabilities[42] - The company has completed the technical development of high-activity probiotic raw materials for dairy products, improving production efficiency and reducing costs by over 30%[70] - The company has made significant investments in research and development, focusing on products that align with market trends and consumer health needs[69] Market Trends and Opportunities - The health supplement industry in China reached a sales figure of 198.4 billion yuan in 2020, showing a year-on-year growth of 11.52%[33] - The projected market size of the health supplement industry is expected to reach approximately 517.8 billion yuan by 2026, maintaining a growth rate of at least 4% over the next five years[33] - The company aims to expand its probiotic product line and enhance its competitive edge through differentiated strategies[87] - The company is focusing on mid-range elderly medical care institutions and deepening its presence in the Yangtze River Delta region[87] Corporate Governance and Compliance - The company has received a standard unqualified audit opinion from Da Xin Accounting Firm[4] - The company maintains independence from its controlling shareholder in terms of assets, personnel, and financial management[101] - The company has established an independent financial accounting department with dedicated personnel and a standardized financial management system[102] - The company has established a performance evaluation system linking executive compensation to business performance[99] Social Responsibility and Environmental Initiatives - The company actively participates in social responsibility initiatives, including health education programs and community support[144] - The company has invested in upgrading wastewater treatment facilities to enhance environmental protection efforts[145] - The company implemented a central air conditioning cooling water system renovation project, expected to save approximately 150 tons of standard coal annually[142] Challenges and Risks - The company faced significant impacts on operations and business due to the COVID-19 pandemic, affecting the opening and occupancy rates of its facilities[151] - The company is exposed to risks from policy changes affecting healthcare payments and rising labor costs in the medical care sector[93] - The healthcare food industry faces increasing regulatory scrutiny, necessitating compliance with new laws and internal management standards[92]

Financial Performance - Q1 2022 revenue was CNY 91,400,747.06, a decrease of 1.57% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 9,167,962.88, down 43.76% year-on-year[3] - Basic earnings per share decreased by 42.86% to CNY 0.012[3] - Total operating revenue for Q1 2022 was CNY 91,400,747.06, a decrease of 1.6% from CNY 92,854,861.84 in Q1 2021[18] - Net profit for Q1 2022 was CNY 12,364,513.47, compared to CNY 18,876,329.99 in Q1 2021, indicating a decline of 34.4%[19] - Total comprehensive income for Q1 2022 was CNY 13,164,513.47, a decrease from CNY 19,814,419.90 in Q1 2021[20] - Basic and diluted earnings per share for Q1 2022 were CNY 0.012, down from CNY 0.021 in Q1 2021[20] Cash Flow and Liquidity - Net cash flow from operating activities was negative CNY 7,096,727.48, a decline of 362.98%[3] - The company's cash and cash equivalents decreased to CNY 308,851,349.44 in Q1 2022 from CNY 332,098,052.13 in Q1 2021, indicating liquidity challenges[18] - Cash received from sales of goods and services in Q1 2022 was CNY 85,158,920.06, an increase from CNY 80,738,031.10 in Q1 2021[22] - Cash paid for purchasing goods and services in Q1 2022 was CNY 31,837,059.98, up from CNY 23,802,468.08 in Q1 2021[23] - Net cash flow from investing activities for Q1 2022 was CNY -19,423,006.75, a decrease from CNY 5,267,523.83 in Q1 2021[23] - Total cash outflow from financing activities in Q1 2022 was CNY 8,620,187.28, compared to CNY 63,685,066.66 in Q1 2021[24] - The company reported a decrease in cash received from other operating activities, totaling CNY 5,210,181.56 in Q1 2022, down from CNY 11,824,472.93 in Q1 2021[23] - The company experienced a foreign exchange loss of CNY -33,641.02 in Q1 2022, compared to a gain of CNY 115,501.64 in Q1 2021[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,381,665,800.16, an increase of 2.17% from the end of the previous year[4] - The total liabilities for Q1 2022 were CNY 454,932,189.07, compared to CNY 438,776,105.37 in Q1 2021, showing an increase in financial obligations[17] - The equity attributable to shareholders increased to CNY 885,818,611.88 in Q1 2022 from CNY 875,850,649.00 in Q1 2021, reflecting a stable capital position[18] Shareholder Changes - A total of 124,590,064 shares, representing 15.97% of the total share capital, were transferred through agreements among major shareholders during the reporting period[12] - After the transfer, Shanghai Yunjian Industrial Development Co., Ltd. and its concerted actors held a total of 124,590,064 shares, which is 15.97% of the total share capital[13] - The major shareholder, Shanghai New South Ocean Anli Education Technology Co., Ltd., currently holds 66,446,889 shares, accounting for 8.52% of the total share capital[10] - The company has seen significant changes in its major shareholders, with the transfer of 39,072,641 shares (5.01% of total capital) to Lishui Nongbang Consulting Partnership[10] - The company’s major shareholders, including Zhongjin Investment Group Co., Ltd., have undergone significant share transfers, impacting their ownership structure[11] Research and Development - R&D expenses increased by 29.23% as the company intensified its investment in research and development[6] - The company's R&D expenses increased to CNY 4,223,086.94 in Q1 2022, up from CNY 3,267,947.35 in Q1 2021, highlighting a focus on innovation[18] Other Observations - The company reported a 100.10% decrease in asset disposal gains compared to the same period last year[6] - The company’s financial statements for the first quarter of 2022 are unaudited, indicating a need for caution in interpreting the financial data[14] - The company has not reported any significant new strategies or product developments during the quarter[14] - The company's trading financial assets remained stable at RMB 12,141,976.76 as of March 31, 2022, unchanged from the previous period[15] - Accounts receivable increased by 18.86% due to impacts from the pandemic[5] - The company reported accounts receivable of RMB 98,573,920.46 as of March 31, 2022, compared to RMB 83,059,404.14 as of December 31, 2021, indicating an increase of approximately 18.8%[15] - Cash and cash equivalents at the end of Q1 2022 were CNY 128,257,038.56, compared to CNY 62,408,602.84 at the end of Q1 2021[24] - The company reported an investment loss of CNY 20,566.74 in Q1 2022, compared to a gain of CNY 10,013.47 in Q1 2021, indicating challenges in investment performance[19] - The company’s short-term borrowings remained stable at CNY 50,000,000.00 in both Q1 2022 and Q1 2021, reflecting a consistent financing strategy[17]

Revenue and Profit - Revenue for Q3 2021 was CNY 83,091,191.37, a decrease of 12.96% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 3,329,275.88, down 86.08% year-on-year[4] - Net profit excluding non-recurring gains and losses increased by 33.54% to CNY 2,729,348.01[4] - Basic earnings per share decreased by 86.67% to CNY 0.004[5] - Total operating revenue for the first three quarters of 2021 reached ¥261,489,542.54, an increase from ¥251,919,577.93 in the same period of 2020, representing a growth of approximately 3.5%[19] - Net profit for the third quarter of 2021 was ¥27,449,953.98, down from ¥57,422,437.31 in the same quarter of 2020, reflecting a decline of approximately 52.2%[20] - The comprehensive income total for the third quarter of 2021 was ¥28,666,043.89, down from ¥59,877,397.08 in the same quarter of 2020, reflecting a decline of about 52.1%[21] - Basic earnings per share for the third quarter of 2021 were ¥0.030, down from ¥0.070 in the same quarter of 2020, reflecting a decrease of approximately 57.1%[21] Assets and Liabilities - Total assets increased by 5.90% to CNY 1,370,284,431.99 compared to the end of the previous year[5] - The company's total liabilities as of the third quarter of 2021 amounted to ¥471,269,524.81, an increase from ¥421,332,215.02 in the previous year, showing a rise of about 11.9%[18] - The total assets as of Q3 2021 were CNY 1,293,961,078.31, reflecting a decrease from CNY 1,432,862,354.87 at the beginning of the year[28] - The company’s total liabilities decreased to CNY 1,022,196,636.45 from CNY 1,161,097,913.01 at the start of the year[28] - Total liabilities amounted to ¥421,332,215.02, a decrease of ¥138,901,276.56 compared to the previous period[29] - Current liabilities totaled ¥246,260,471.39, while non-current liabilities were ¥175,071,743.63[29] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 30,493[11] - The largest shareholder, Dazhong Transportation Group, holds 16.37% of shares[11] - Shanghai Xinnanyang Angli Education Technology Co., Ltd. is the second-largest shareholder with a 13.53% stake[11] - The total equity attributable to shareholders reached ¥860,906,742.64, compared to ¥834,900,061.69 in the same period last year, marking an increase of approximately 3.1%[18] Cash Flow - Cash flow from operating activities increased by 67.59% to CNY 59,767,073.49 year-to-date[4] - Cash flow from operating activities for the first three quarters of 2021 was ¥266,397,229.75, compared to ¥246,752,497.20 in 2020, representing an increase of about 7.9%[23] - Net cash flow from operating activities for Q3 2021 was CNY 59,767,073.49, an increase of 67.5% compared to CNY 35,663,404.09 in Q3 2020[24] - Total cash inflow from investment activities was CNY 10,857,624.99, a decrease of 80.6% from CNY 55,913,541.19 in the previous year[24] - Cash flow from financing activities showed a net outflow of CNY 54,001,226.48, compared to a net outflow of CNY 129,196,439.61 in Q3 2020[25] Operational Costs and Expenses - Total operating costs for the first three quarters of 2021 were ¥239,402,966.95, compared to ¥221,565,183.14 in 2020, indicating an increase of about 8.0%[19] - Research and development expenses for the first three quarters of 2021 were ¥10,498,101.06, up from ¥8,316,124.31 in 2020, indicating a growth of about 26.3%[19] Strategic Relationships - The company has established a strategic relationship with its major shareholders, indicating potential for future collaboration and market expansion[13]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥178,398,351.17, representing a 14.03% increase compared to ¥156,449,097.57 in the same period last year[18]. - The net profit attributable to shareholders decreased by 33.33% to ¥20,424,555.96 from ¥30,635,518.42 year-on-year[18]. - The net profit after deducting non-recurring gains and losses increased by 57.64% to ¥16,289,819.66 compared to ¥10,333,409.12 in the previous year[18]. - The net cash flow from operating activities rose by 58.80% to ¥39,080,452.35 from ¥24,610,520.33 in the same period last year[18]. - Basic earnings per share decreased by 33.33% to ¥0.026 from ¥0.039 in the same period last year[19]. - The total comprehensive income for the first half of 2021 was ¥24,344,292.52, compared to ¥30,538,533.62 in the same period of 2020, a decrease of 20.3%[93]. - The company reported a net loss of CNY 111,154,081.94, improving from a loss of CNY 131,578,637.90 in the previous period[85]. - The company reported a total comprehensive income loss of CNY 1,905,988.20 during the current period, indicating a significant decline compared to the previous period[114]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,326,239,362.81, a 2.49% increase from ¥1,293,961,078.31 at the end of the previous year[18]. - Total liabilities amounted to CNY 431,546,207.00, slightly up from CNY 421,332,215.02, indicating a growth of 2.9%[85]. - Current assets totaled CNY 251,156,922.33, a decrease of 7.6% from CNY 271,764,441.86 at the end of 2020[84]. - Cash and cash equivalents decreased to CNY 86,402,028.05 from CNY 118,012,055.66, a decline of 26.9%[83]. - Total equity attributable to shareholders was CNY 834,900,061.69 at the beginning of the year, with a total equity of CNY 872,628,863.29 by the end of the reporting period[106]. Market and Industry Trends - The company's health supplement segment focuses on the research, production, and sales of food and health food products, with a significant increase in market demand due to changing consumer attitudes post-COVID-19[26]. - The health supplement market in China is projected to grow to CNY 270.8 billion by 2021, driven by a shift from optional to essential consumption[26]. - The elderly population in China is projected to reach 18.7% by 2027, increasing the demand for medical and nursing services[29]. - The health supplement market is experiencing a trend towards younger consumer demographics and diverse consumption scenarios, indicating vast market potential[26]. Research and Development - The company has obtained 34 national patent authorizations, including 9 for probiotic inventions, showcasing its strong R&D capabilities[30]. - Research and development expenses increased by 21.73% to ¥7.08 million, up from ¥5.82 million, reflecting the company's commitment to innovation[36]. - The company emphasizes technological innovation and has increased investment in R&D to maintain its competitive edge in the industry[30]. Operational Highlights - The company operates five self-owned profit-making elderly medical care institutions, generating revenue from medical care, rehabilitation, and catering services[28]. - The occupancy rate of the medical care segment has recovered to pre-pandemic levels, with an overall increase of approximately 1.5% compared to the end of 2020[34]. - The company has established a standardized operational system and strict quality control standards, enhancing its reputation in the industry[32]. Corporate Governance - The company held two shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[52]. - The company appointed new directors, including Zhao Siyuan, Ma Hebo, and Tang Daoqing, as well as independent directors Li Xia and Qiao Yutuan, during the board election[53]. - The company did not propose any profit distribution or capital reserve transfer plans for the first half of 2021, with no dividends or stock bonuses declared[55]. Risks and Challenges - The company faces risks from intensified industry competition, particularly from international enterprises entering the Chinese market and the rise of e-commerce[47]. - The company is at risk of policy changes affecting medical insurance and long-term care insurance, which significantly impact its operational revenue[47]. - Labor costs are a major concern, as the healthcare industry is labor-intensive, with personnel costs comprising a large portion of total operating expenses[47]. Environmental and Social Responsibility - The company undertook energy-saving modifications to its central air conditioning system, expected to save 150 tons of standard coal annually[59]. - The company conducted CCTV and QVU inspections of its rain and sewage pipelines, and upgraded its wastewater treatment facilities[60]. - The company has not disclosed any environmental penalties or issues during the reporting period[57]. Financial Management - The company maintains a stable financial position with no significant debt financing tools in use[81]. - The company plans to continue its focus on enhancing its capital structure and optimizing its financial performance in the upcoming quarters[108]. - The company has allocated resources towards research and development to drive innovation and market expansion[110]. Shareholder Information - The largest shareholder, Dazhong Transportation (Group) Co., Ltd., held 143,184,187 shares, accounting for 18.36% of the total shares[75]. - The company completed a share buyback of 5,080,000 shares, which is 0.6513% of the total share capital, with a total expenditure of RMB 25,006,950[76]. - The company has a total of 34,561 ordinary shareholders at the end of the reporting period[73].

Financial Performance - In 2020, the company achieved a revenue of CNY 332,695,487.68, a slight increase of 0.03% compared to CNY 332,602,654.23 in 2019[20] - The net profit attributable to shareholders was CNY 92,670,121.92, a significant turnaround from a loss of CNY 77,794,294.01 in 2019, representing a 219.12% increase[20] - Basic earnings per share for 2020 were CNY 0.119, compared to a loss of CNY 0.10 in 2019, marking a 219% improvement[21] - The company's total revenue for 2020 was CNY 333 million, a slight increase of 0.03% compared to the previous year[39] - The net profit attributable to shareholders for 2020 was CNY 93 million, representing a significant year-on-year growth of 219.12%[39] - The medical and nursing segment achieved a net profit of CNY 54.7 million in 2020, up from CNY 35.8 million in the previous year[39] - Total operating revenue for the year was CNY 319,255,077.09, an increase of 7.41% compared to the previous year[43] - The company reported a net profit of 4,099.32 million yuan for Horgos Renheng Medical Care Management Co., Ltd., with total assets of 5,217.04 million yuan[72] Assets and Liabilities - The total assets of the company decreased by 8.61% to CNY 1,293,961,078.31 from CNY 1,415,800,418.59 in 2019[20] - Cash and cash equivalents decreased by 35.10% to ¥118,012,055.66 from ¥181,840,564.39 due to loan repayments[52] - Trading financial assets decreased by 55.48% to ¥13,286,110.47 from ¥29,840,202.52 as a result of the disposal of Tai Ling Pharmaceutical[53] - Total liabilities decreased from CNY 623,647,520.87 in 2019 to CNY 421,332,215.02 in 2020, a decrease of approximately 32.5%[164] - Short-term borrowings decreased from CNY 160,000,000.00 in 2019 to CNY 80,000,000.00 in 2020, a 50% decrease[164] - Long-term borrowings decreased from CNY 210,000,000.00 in 2019 to CNY 132,000,000.00 in 2020, a decline of about 37.14%[164] - The company's total equity increased from CNY 792,152,897.72 in 2019 to CNY 872,628,863.29 in 2020, an increase of approximately 10.1%[164] Cash Flow - The company's net cash flow from operating activities was CNY 67,178,715.33, down 32.19% from CNY 99,064,926.35 in 2019[20] - The company experienced a cash flow from operating activities of CNY -9.24 million in Q1, but recovered to CNY 33.85 million in Q2[22] - The net cash flow from operating activities increased significantly to ¥68,606,402.10 in 2020, compared to ¥16,942,429.43 in 2019, representing a growth of approximately 304.5%[179] - The net cash flow from investing activities turned positive at RMB 83,269,976.56, a recovery from a negative cash flow of RMB -250,275,700.60 in 2019[177] Expenses and Costs - Operating costs increased by 25.66% to CNY 191.8 million, compared to CNY 152.6 million in the previous year[40] - Sales expenses decreased by 50.60% to CNY 44 million, down from CNY 89.1 million[40] - Management expenses were reduced by 35.85% to CNY 44.3 million, compared to CNY 69 million in the previous year[40] - Research and development expenses decreased by 28.57% to CNY 12.8 million, down from CNY 17.9 million[40] Market and Business Strategy - The company’s main business includes the R&D, production, and sales of food and health products, as well as the operation and management of elderly medical care institutions[29] - The health product sector is experiencing an upward demand cycle, with significant growth potential driven by government policies promoting health and disease prevention[29] - The company is focusing on digital transformation and innovative business models to adapt to changing consumer behaviors post-COVID-19[29] - The company is focusing on acquiring nursing home projects and disposing of non-operating assets to concentrate on its core business[36] - The aging population in China is projected to continue growing, with over 255 million people aged 60 and above by 2020, highlighting the demand for medical and nursing services[32] Research and Development - The company has developed new probiotic products suitable for diabetes patients and received a patent for the product formula[60] - The company completed major R&D projects, including the development of a solid throat lozenge with cough relief and anti-inflammatory properties[61] - The company is exploring key technologies for high-activity probiotic raw materials applicable to dairy products[61] - The company has made significant investments in R&D, with a focus on improving the viability of lactic acid bacteria and reducing production costs[65] Corporate Governance - The company has a total of 8 independent directors and 5 supervisors, ensuring a robust governance structure[125] - The board of directors consists of 11 members, including 4 independent directors, complying with legal requirements[141] - The company is committed to transparency and compliance with corporate governance standards[131] - The company has established a performance evaluation system linking management compensation to business performance[141] Social Responsibility and Environmental Impact - The company has actively participated in social responsibility activities, including donating RMB 1 million worth of products to medical institutions during the pandemic[101] - The company has invested in environmental protection measures, including upgrading wastewater treatment facilities to reduce COD and BOD levels effectively[102] - The company has not experienced any environmental pollution incidents or received administrative penalties from environmental protection departments during the reporting period[102] Risks and Challenges - The company faces increasing competition from international enterprises entering the Chinese market and the rise of new media and technology applications[78] - The company is exposed to policy risks related to healthcare insurance and long-term care insurance, which could impact its operational stability[78] - The COVID-19 pandemic has affected the occupancy rates and revenue of the company's elderly care institutions, leading to potential declines in revenue and increased operational costs[78]

Financial Performance - Operating revenue rose by 10.67% to CNY 92,854,861.84 year-on-year[7] - Net profit attributable to shareholders decreased by 9.95% to CNY 16,302,514.71 compared to the same period last year[7] - Basic and diluted earnings per share both decreased by 8.70% to CNY 0.021[7] - Total operating revenue for Q1 2021 was CNY 92,854,861.84, an increase of 10.4% compared to CNY 83,907,625.51 in Q1 2020[29] - Net profit for Q1 2021 was CNY 18,876,329.99, a slight increase from CNY 18,454,933.98 in Q1 2020, representing a growth of 2.3%[29] - The net profit attributable to shareholders of the parent company was CNY 16,302,514.71, down from CNY 18,103,106.64 in the previous year, a decrease of 9.9%[30] - The company reported a total comprehensive income of CNY 19,814,419.90 for Q1 2021, compared to CNY 18,464,102.98 in Q1 2020, an increase of 7.3%[30] - The company’s total profit for Q1 2021 was CNY 4,226,170.08, a stark contrast to a total loss of CNY -5,992,281.97 in Q1 2020, indicating a strong recovery trajectory[32] Cash Flow - Net cash flow from operating activities improved significantly, reaching CNY 2,698,588.37, a 129.20% increase from the previous year[7] - The net cash flow from operating activities for the current period was ¥2,698,588.37, a significant increase of 129.20% compared to the previous period's net cash flow of -¥9,242,134.47[17] - The company recorded a total cash inflow from operating activities of CNY 93,325,816.01, an increase from CNY 70,711,771.64 in the previous year, representing a growth of about 32%[33] - Operating cash flow for Q1 2021 was CNY 2,698,588.37, compared to a negative cash flow of CNY -9,242,134.47 in the same period last year, indicating improved operational efficiency[33] - The net cash flow from operating activities for Q1 2021 was ¥24,113,478.24, a decrease from ¥59,535,077.05 in Q1 2020, reflecting a decline of approximately 59.6%[37] Assets and Liabilities - Total assets increased by 5.99% to CNY 1,371,452,232.88 compared to the end of the previous year[7] - Current assets decreased to ¥224,277,876.55 from ¥271,764,441.86 at the end of 2020[20] - The total liabilities as of March 31, 2021, were ¥479,008,949.69, compared to ¥421,332,215.02 at the end of 2020[22] - The company's equity attributable to shareholders increased to ¥852,140,666.31 from ¥834,900,061.69 at the end of 2020[22] - Total liabilities were CNY 372,711,757.72, showing a marginal increase from CNY 371,656,519.68[25] - The total current assets were $315,117,109.13, showcasing liquidity strength[44] Cash and Cash Equivalents - Cash and cash equivalents decreased by 47.12% to CNY 62,408,602.84 due to loan repayments[15] - The company's cash and cash equivalents decreased to ¥62,408,602.84 from ¥118,012,055.66 at the end of 2020[20] - The company's cash and cash equivalents decreased to CNY 295,755,259.68 from CNY 315,117,109.13, a decline of 6.5%[25] - Cash and cash equivalents at the end of Q1 2021 stood at CNY 62,408,602.84, down from CNY 83,679,539.32 at the end of Q1 2020, a decrease of approximately 25%[34] - The cash and cash equivalents at the end of Q1 2021 were ¥6,094,167.03, down from ¥44,038,576.84 at the end of Q1 2020, indicating a decrease of about 86.1%[37] Investment and Financing Activities - The net cash flow from investing activities decreased by 54.71%, amounting to ¥5,267,523.83, down from ¥11,630,203.02 in the previous period[17] - The company’s investment activities generated a net cash inflow of CNY 5,267,523.83 in Q1 2021, compared to CNY 11,630,203.02 in Q1 2020, indicating a decline in investment returns[34] - The net cash flow from financing activities improved by 36.71%, with a current value of -¥63,685,066.66 compared to -¥100,621,417.39 in the previous period[17] - The company’s financing activities resulted in a net cash outflow of CNY -63,685,066.66 in Q1 2021, an improvement from a net outflow of CNY -100,621,417.39 in the same period last year[34] Cost Management - The company reported a decrease in management expenses due to reduced consulting fees, contributing to overall cost management[18] - Total operating costs decreased to CNY 79,791,326.54 from CNY 80,764,798.72, reflecting a reduction of 1.2%[29] - Research and development expenses for Q1 2021 were CNY 3,267,947.35, slightly down from CNY 3,348,068.21 in the previous year[29]